Show simple item record

dc.contributor.authorBrown, RB
dc.contributor.authorTozer, DJ
dc.contributor.authorLoubière, L
dc.contributor.authorHong, YT
dc.contributor.authorFryer, TD
dc.contributor.authorWilliams, GB
dc.contributor.authorGraves, MJ
dc.contributor.authorAigbirhio, FI
dc.contributor.authorO’Brien, JT
dc.contributor.authorMarkus, HS
dc.date.accessioned2022-05-23T23:30:12Z
dc.date.available2022-05-23T23:30:12Z
dc.date.issued2022
dc.identifier.issn2396-9873
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337407
dc.description.abstract<jats:sec><jats:title>Background:</jats:title><jats:p> Cerebral small vessel disease (SVD) is a common cause of stroke and cognitive impairment. Recent data has implicated neuroinflammation and increased blood-brain barrier (BBB) permeability in its pathogenesis, but whether such processes are causal and can be therapeutically modified is uncertain. In a rodent model of SVD, minocycline was associated with reduced white matter lesions, inflammation and BBB permeability. </jats:p></jats:sec><jats:sec><jats:title>Aims:</jats:title><jats:p> To determine whether blood-brain barrier permeability (measured using dynamic contrast-enhanced MRI) and microglial activation (measured by positron emission tomography using the radioligand <jats:sup>11</jats:sup>C-PK11195) can be modified in SVD. </jats:p></jats:sec><jats:sec><jats:title>Design:</jats:title><jats:p> Phase II randomised double blind, placebo-controlled trial of minocycline 100 mg twice daily for 3 months in 44 participants with moderate to severe SVD defined as a clinical lacunar stroke and confluent white matter hyperintensities. </jats:p></jats:sec><jats:sec><jats:title>Outcomes:</jats:title><jats:p> Primary outcome measures are volume and intensity of focal increases of blood-brain barrier permeability and microglial activation determined using PET-MRI imaging. Secondary outcome measures include inflammatory biomarkers in serum, and change in conventional MRI markers and cognitive performance over 1 year follow up. </jats:p></jats:sec><jats:sec><jats:title>Discussion:</jats:title><jats:p> The MINERVA trial aims to test whether minocycline can influence novel pathological processes thought to be involved in SVD progression, and will provide insights into whether central nervous system inflammation in SVD can be therapeutically modulated. </jats:p></jats:sec>
dc.publisherSAGE Publications
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleMINocyclinE to Reduce inflammation and blood brain barrier leakage in small Vessel diseAse (MINERVA) trial study protocol
dc.typeArticle
dc.publisher.departmentDepartment of Clinical Neurosciences
dc.date.updated2022-05-20T11:02:47Z
prism.endingPage239698732211003
prism.publicationNameEuropean Stroke Journal
prism.startingPage239698732211003
dc.identifier.doi10.17863/CAM.84819
dcterms.dateAccepted2022-04-24
rioxxterms.versionofrecord10.1177/23969873221100338
rioxxterms.versionVoR
dc.contributor.orcidBrown, RB [0000-0003-0431-7841]
dc.contributor.orcidWilliams, GB [0000-0001-5223-6654]
dc.identifier.eissn2396-9881
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (MR/N026896/1)
cam.issuedOnline2022-05-17
cam.depositDate2022-05-20
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International